Engineered Nanoparticles inside a Microparticle Oral System for Enhanced Mucosal and Systemic Immunity

ACS Appl Mater Interfaces. 2022 Mar 9;14(9):11124-11143. doi: 10.1021/acsami.1c24982. Epub 2022 Feb 28.

Abstract

Antigen delivery through an oral route requires overcoming multiple challenges, including gastrointestinal enzymes, mucus, and epithelial tight junctions. Although each barrier has a crucial role in determining the final efficiency of the oral vaccination, transcytosis of antigens through follicle-associated epithelium (FAE) represents a major challenge. Most of the research is focused on delivering an antigen to the M-cell for FAE transcytosis because M-cells can easily transport the antigen from the luminal site. However, the fact is that the M-cell population is less than 1% of the total gastrointestinal cells, and most of the oral vaccines have failed to show any effect in clinical trials. To challenge the current dogma of M-cell targeting, in this study, we designed a novel tandem peptide with a FAE-targeting peptide at the front position and a cell-penetrating peptide at the back position. The tandem peptide was attached to a smart delivery system, which overcomes the enzymatic barrier and the mucosal barrier. The result showed that the engineered system could target the FAE (enterocytes and M-cells) and successfully penetrate the enterocytes to reach the dendritic cells located at the subepithelium dome. There was successful maturation and activation of dendritic cells in vitro confirmed by a significant increase in maturation markers such as CD40, CD86, presentation marker MHC I, and proinflammatory cytokines (TNF-α, IL-6, and IL-10). The in vivo results showed a high production of CD4+ T-lymphocytes (helper T-cell) and a significantly higher production of CD8+ T-lymphocytes (killer T-cell). Finally, the production of mucosal immunity (IgA) in the trachea, intestine, and fecal extracts and systemic immunity (IgG, IgG1, and IgG2a) was successfully confirmed. To the best of our knowledge, this is the first study that designed a novel tandem peptide to target the FAE, which includes M-cells and enterocytes rather than M-cell targeting and showed that a significant induction of both the mucosal and systemic immune response was achieved compared to M-cell targeting.

Keywords: FAE targeting; mucosal immunity; oral vaccine; systemic immunity; tandem peptide.

MeSH terms

  • Administration, Oral
  • Animals
  • Antigens / immunology
  • Cell Line
  • Cell Survival / drug effects
  • Cytokines / metabolism
  • Female
  • Humans
  • Hydrogen-Ion Concentration
  • Immunity
  • Immunity, Mucosal / drug effects*
  • Immunoglobulin A / metabolism
  • Immunoglobulin G / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry*
  • Nanoparticles / toxicity
  • Ovalbumin / immunology
  • Peyer's Patches / immunology
  • Spleen / drug effects
  • Th1 Cells / metabolism
  • Th2 Cells
  • Vaccines / administration & dosage
  • Vaccines / chemical synthesis
  • Vaccines / chemistry
  • Vaccines / pharmacokinetics

Substances

  • Antigens
  • Cytokines
  • Immunoglobulin A
  • Immunoglobulin G
  • Vaccines
  • Ovalbumin